Home › Companies › ANAB

ANAPTYSBIO, INC

ANAB Rare disease Lead: Approved 7 Biotech Distilled articles ↓

Dermatology GI/Hepatology Immunology Oncology Protein

Most recent annual filing: 2026-03-03

Pipeline (6 active programs)

rosnilimab

Protein Target: PD-1

Rheumatoid Arthritis Phase 2 subcutaneous

ANB033

Protein Target: CD122

Celiac Disease Phase 1 subcutaneous
Eosinophilic Esophagitis Phase 1

ANB101

Protein Target: BDCA2

Undisclosed indication Phase 1

Jemperli

dostarlimab-gxly

Protein Target: PD-1

Endometrial Cancer Approved GSK

imsidolimab

Protein Target: IL-36R

Generalized Pustular Psoriasis Phase 3 Vanda Pharmaceuticals Inc.

Biotech Distilled coverage (7)

2026-05-21 UPDATE: AnaptysBio (ANAB) - The Fiscal Year Gets a Royalty Co. Makeover 🔒 Paid
2026-05-12 UPDATE: AnaptysBio (ANAB) - The First Pure-Royalty Quarter Prints 🔒 Paid
2026-05-12 UPDATE: AnaptysBio (ANAB) - The Board Is Now a Royalty Aggregator Starter Pack 🔒 Paid
2026-04-27 UPDATE: AnaptysBio (ANAB) - The Court Strikes the First Blow. Tesaro Loses. 🔒 Paid
2026-03-28 UPDATE: AnaptysBio (ANAB) - The AnaptysBio Divorce is Finalized. Let the Arbitrage Begin. 🔒 Paid
2026-03-08 UPDATE: AnaptysBio (ANAB): A Divorce is Imminent, and Jemperli is Paying the Alimony 🔒 Paid
2026-02-12 AnaptysBio Inc (ANAB): Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.